Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study
Conclusion:
MSI status and PD-L1 expression are clinically actionable biomarkers for stratifying patients and predicting benefit from adjuvant chemotherapy after D2 gastrectomy for stage II/III gastric cancer.
Source: Annals of Surgery - Category: Surgery Tags: ORIGINAL ARTICLES Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Eloxatin | Gastrectomy | Gastric (Stomach) Cancer | Gastroenterology | Study | Surgery | Xeloda